Breaking Down SG&A Expenses: Zoetis Inc. vs Cytokinetics, Incorporated

Zoetis vs. Cytokinetics: SG&A Expense Trends Unveiled

__timestampCytokinetics, IncorporatedZoetis Inc.
Wednesday, January 1, 2014172680001643000000
Thursday, January 1, 2015196670001532000000
Friday, January 1, 2016278230001364000000
Sunday, January 1, 2017364680001334000000
Monday, January 1, 2018312820001484000000
Tuesday, January 1, 2019396100001638000000
Wednesday, January 1, 2020528200001726000000
Friday, January 1, 2021968030002001000000
Saturday, January 1, 20221779770002009000000
Sunday, January 1, 20231736120002151000000
Monday, January 1, 20242318000000
Loading chart...

Unleashing insights

SG&A Expenses: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, understanding the financial dynamics of companies like Zoetis Inc. and Cytokinetics, Incorporated is crucial. Over the past decade, Zoetis has consistently outpaced Cytokinetics in Selling, General, and Administrative (SG&A) expenses, reflecting its expansive market reach and operational scale. In 2023, Zoetis reported SG&A expenses that were nearly 12 times higher than those of Cytokinetics, highlighting its significant investment in marketing and administrative functions.

A Decade of Growth

From 2014 to 2023, Zoetis's SG&A expenses grew by approximately 31%, while Cytokinetics saw a staggering increase of over 900%. This dramatic rise for Cytokinetics underscores its aggressive growth strategy and increasing market presence. As these companies continue to evolve, their financial strategies will play a pivotal role in shaping their future trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025